Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

NCT06904196 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

COMBINATION_PRODUCT: Lenvatinib plus SIRT
DRUG: Lenvatinib

Sponsor

Second Affiliated Hospital of Guangzhou Medical University